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Abstract
Background: Concurrent chemoradiation therapy (CCRT) followed by hepatic arterial infusional chemotherapy
(HAIC) was reported to be effective for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis.
However, transarterial chemoembolization (TACE) is not preferred in this setting. The aim of this study was to assess
the factors affecting survival after CCRT, including additional TACE during repeated HAIC.
Methods: Thirty-eight patients who underwent CCRT as the initial treatment for Barcelona Clinic Liver Cancer stage
C HCC with vascular invasion between 2009 and 2016 were reviewed retrospectively. During CCRT, 5-fluorouracil (5-
FU) was infused via chemoport during the first and last five days of five weeks of external beam radiation therapy.
After CCRT, repeated HAIC with cisplatin and 5-FU was performed monthly. Nineteen patients (50%) underwent
additional TACE between repeated HAICs. Factors related to overall survival and progression free survival (PFS) were
analyzed.
Results: The mean age of patients was 55 years (male:female, 33:5). Underlying liver diseases were hepatitis B, hepatitis
C and non-B/C in 29, 1 and 8 patients, respectively. The median radiation dose was 4500 cGy. The objective response
(OR) rate at one months after CCRT was 36.8%. The median PFS was 7.4 (range, 1.8 − 32.1) months. The median overall
survival was 11.6 (range 2.8-65.7) months. Achieving an OR after CCRT (hazard ratio [HR], 0.028; P < 0.001), additional
TACE (HR, 0.134, P < 0.001), and further rounds of HAIC (HR, 0.742, P = 0.001) were independent significant factors
related to overall survival. The overall survival duration of patients with an OR after CCRT (median 44.2 vs. 6.6 months,
P < 0.001) and additional TACE (median 19.8 vs. 9.1 months, P = 0.001) were significantly greater than those without an
OR after CCRT or additional TACE.
Conclusion: Patients who achieved an OR after CCRT, underwent additional TACE, and were subjected to repeated
rounds of HAIC following CCRT showed better survival after CCRT for advanced stage of HCC with vascular invasion. A
further prospective study is needed to confirm the positive effect of additional TACE after CCRT.
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Background
Hepatocellular carcinoma (HCC) is the seventh-most
common cancer in females and the fifth-most common
cancer in males worldwide [1]. It is the second-most com-
mon cause of cancer-related deaths in males worldwide,
with more than 500,000 deaths reported annually [2].
Viral hepatitis is the main cause of HCC, and endemic
areas of viral hepatitis have a huge burden of this disease.
Since HCC is mostly asymptomatic, it is often detected
at an advanced stage. Approximately one third of pa-
tients with HCC show macrovascular invasion, including
portal vein thrombosis, on radiologic imaging [3]. Portal
vein invasion of HCC is considered to represent aggres-
sive tumor behavior and contribute to a higher risk of
mortality [4]. According to the Barcelona Clinic Liver
Cancer (BCLC) staging system, which is endorsed by the
American Association for the Study of Liver Diseases
and the European Association for the Study of the Liver,
portal vein invasion of HCC is designated as advanced-
stage HCC, and sorafenib is the recommended standard
of care [5]. However, the Sorafenib Hepatocellular
Carcinoma Assessment Randomized Protocol (SHARP)
and Asia-Pacific SHARP trial showed a modest survival
gain with sorafenib [6, 7]; therefore, new treatment strat-
egies for portal vein invasion of HCC are required.
The Korean Liver Cancer Study Group (KLCSG) and
the National Cancer Center (NCC) Korea practice
guidelines and the Asia-Pacific Primary Liver Cancer
Expert consortium recommend radiotherapy as an
effective treatment for advanced HCC with portal vein
invasion [8, 9]. Because radiotherapeutic strategies are
frequently used in Korea, radiation therapy (RT) is
suggested as an alternative treatment if sorafenib is not
feasible [10]. The protocol of concurrent chemoradiation
therapy (CCRT) followed by repeated hepatic arterial
infusion chemotherapy (HAIC) was first developed for,
and introduced in, patients with locally advanced HCC
with portal vein invasion [11]. The CCRT protocol was
developed before the era of sorafenib [11], when HAIC,
transarterial chemoembolization (TACE), and RT were
used to treat of advanced-stage HCC in Asian countries.
Therefore, to increase the therapeutic effect, HAIC was
added to deliver chemotherapeutic agents to HCC after
CCRT. HAIC delivers chemotherapeutic agents at high
concentrations through a chemoport. This results in the
drug going through first-pass metabolism in the liver,
which reduces the systemic level of the drug and
decreases its systemic toxicity and side effects [12].
According to the previous report of favorable results [13,
14], HAIC was added to the protocol: HAIC was com-
bined with 5-FU during RT for radiosensitizing effect,
and HAIC was repeated monthly after CCRT to mainten
the antitumor effect. The treatment showed a favorable
objective response (OR) in 18 of 40 patients (45%), with
a median survival duration of 13.1 months [11]. An up-
dated outcomes report indicated that the median sur-
vival duration of 101 patients was 16.7 months. In the
original protocol, HAIC was performed after CCRT, and
HAIC was to be continued until a complete response
was achieved. However, we occasionally experienced a
decreased effect of repeated HAIC, which necessitated
additional treatment for patients undergoing CCRT and
repeated HAIC.
The use of TACE in patients with advanced HCC with
major portal vein invasion is limited due to the possibility
of liver failure and an increased risk of post-treatment
complications [15]. The effect of TACE is also limited in
these patients; multiple sessions of TACE or additive treat-
ments are usually required. Therefore, TACE is generally
not recommended in these patients. However, several
studies have shown that TACE can be performed safely
with no increase in morbidity or mortality [16–18].
Therefore, we tevaluated the efficacy of additional TACE
between repeated HAIC after CCRT, which, to out
knowledge, has not been assessed previously.
This study evaluated the factors affecting survival after
CCRT, including additional TACE during repeated
HAIC, in patients with advanced-stage HCC.
Methods
Patients
CCRT was performed in cases of advanced HCC with vas-
cular invasion and reserved hepatic function, as decided
by an institutional multidisciplinary HCC tumor board.
We retrospectively analyzed patients who were diagnosed
with advanced-stage HCC per the BCLC staging system
and who underwent CCRT as the initial treatment be-
tween 2009 and 2016. We excluded patients who had
intermediate-stage HCC (n = 13), a Child-Pugh score ≥ 9,
Eastern Cooperative Oncology Group (ECOG) perform-
ance status >1, active peptic ulcer, TACE prior to CCRT
(n = 5), no radiologic evaluation after CCRT, bile duct in-
vasion (n = 2), a failed lesion after previous treatment
(n = 2), other malignancy and inadequate hepatorenal
function. Finally, we identified 60 patients who underwent
CCRT, of whom 38 were enrolled in the study.
The institutional review board waived the requirement
for obtaining informed consent for this retrospective
study (No. 3-2017-0164). This study was conducted in
compliance with the Declaration of Helsinki. All authors
had access to the study data and have reviewed and
approved the final manuscript.
Diagnosis and definitions
The diagnosis of HCC was established by histological
confirmation, typical dynamic radiologic findings on
computed tomography (CT) and magnetic resonance
imaging (MRI), or dynamic imaging with an elevated
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level of serum alpha-fetoprotein (AFP; > 200 ng/mL) or
des-carboxy prothrombin (DCP; > 40 mAU/mL) accord-
ing to the KLCSG-NCC Korea guidelines [8]. Portal/
hepatic vein invasion was defined by the presence of an
adjacent thrombus in the portal/hepatic vein confirmed
by at least one imaging modality.
CCRT followed by HAIC with/without TACE
CT-based three-dimensional treatment planning was per-
formed in all patients. The gross tumor volume (GTV)
was defined as radiographically abnormal areas detected
in dynamic liver CT or MRI images. A margin of 0.5–
1 cm in all directions was added to form the clinical target
volume (CTV). Cranio-caudal movement of the liver de-
termined from the range of diaphragmatic movement
measured via fluoroscope or from all respiratory-motion
phases via 4D CT were incorporated into the definition of
the internal target volume (ITV). An additional 5 mm (to
account for set-up error) was added to the ITV to define
the planning target volume (PTV). Radiation was deliv-
ered using a linear accelerator (Elekta, Stockholm,
Sweden) or Helical Tomotherapy (Accuray, Sunnyvale,
CA, USA) with the intention to deliver 95% of the pre-
scribed dose encompassing the PTV [19]. The total dose
was determined by the fraction of the non-cancerous liver
receiving 50% of the isocenter dose (V50%) according to
the Yonsei University dose prescription guidelines. These
guidelines were as follows: if <25% of the non-cancerous
liver received 50% of the isocenter dose, the total dose
should be increased to 59.4 Gy; if it was 25–50%, the dose
should be reduced to 45–54 Gy; if it was 50–75%, the dose
should be 30.6–41.4 Gy; and if it was > 75%, no treatment
should be administered [20].
For concurrent chemotherapy, an indwelling chemoport
was placed to deliver chemotherapeutic agents into the
hepatic artery, along with RT. Subsequently, 5-FU
(500 mg/day) was infused via the chemoport during the
first and last five days of five weeks of external RT. For
HAIC after CCRT, infusion of cisplatin (80 mg/m2 for
1 day) with 5-FU (750 mg/m2 for 3 days) through the che-
moport was performed monthly [11]. In general, the deci-
sion to add TACE during repeated HAIC following CCRT
was made in a multidisciplinary conference when tumor
progression was suspected or a residual tumor persisted
after repeated HAIC following CCRT. TACE was per-
formed by infusion of approximately 10 mL of iodized oil
(lipiodol; Guerbet, Aulnaysous-Bois, France) mixed with
doxorubicin (50 mg) and selective embolization with gel-
atin sponge particles (Gelfoam; Upjohn, Kalamazoo, MI).
Clinical data and response evaluation
Patients’ demographic and baseline clinical informatio-
n—including cause of liver disease, tumor size, Child-
Pugh score, ECOG performance status, and tumor
marker levels—were collected. Four weeks after CCRT,
dynamic imaging (CT or MRI) was performed to evalu-
ate the response to CCRT. Treatment response was eval-
uated as complete response (CR), partial response (PR),
stable disease (SD), or progressive disease (PD) using the
modified response evaluation criteria for solid tumors
[21]. After the first evaluation, follow-up tumor evaluation
was repeated every 8 weeks. The dates of PD and death
were recorded, and the progression-free survival (PFS)
and overall survival (OS) durations were calculated from
the start of CCRT. The OR was defined as the sum of PR
and CR. Disease control was defined as SD, PR, or CR.
Statistical analyses
Continuous variables are presented as means ± standard
deviation or medians (range) and were compared by Stu-
dent’s t-test or the Mann-Whitney test, as appropriate. Re-
peated measures (continuous variables) were compared by
paired t-test or Wilcoxon signed-ranks test, as appropri-
ate. Categorical variables were compared using Pearson’s
chi-squared test. Local control, PFS, and OS rates were
estimated by Kaplan-Meier analysis and compared using
the log-rank test. Predictors of PFS and OS were identified
by Cox regression analysis. Variables with P < 0.05 in the
univariate analyses were entered into a Cox multivariate
analysis. Hazard ratios and 95% confidence intervals were
calculated. A P-value <0.05 was considered to indicate
significance. To overcome the limitations imposed by the
small sample size, backward-method Cox regression ana-
lyses were performed to identify minimum of clinically
important variables using P < 0.05 for entry and P > 0.051
for removal in the stepwise procedure. All statistical tests
were performed using PASW ver. 17.0 software (IBM
Corp. Armonk, NY, USA).
Results
Patients’ characteristics
The baseline characteristics of the 38 patients enrolled in
the study are shown in Table 1. The mean age was
55 years, and 86.8% of the patients were male. The most-
common etiology of chronic liver disease was hepatitis B
(76.3%). Liver cirrhosis was present in 30 patients (78.9%),
and most patients (84.2%) were Child-Pugh class A. The
mean tumor size was 11.5 cm. Main portal trunk invasion
was noted in 16 patients (42.1%), and node metastasis was
noted in 16 patients (42.1%). The mean and median serum
AFP levels were 8460 and 1573 ng/mL, respectively. The
mean and median serum DCP levels were 24,772 and 420
mAU/mL, respectively. The median radiation dose was
4500 cGy (range, 3060-6250 cGy).
Response after CCRT and decision to perform TACE
One month after CCRT, the mean tumor size decreased
significantly from 11.5 cm to 8.6 cm (P < 0.001).
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Fourteen patients (36.8%) showed a PR, and six patients
(15.8%) showed HCC progression (Table 2). The median
duration of local control was 31 months, and the one-year
local control rate of CCRT was 63.8% by Kaplan-Meier
analysis. The median AFP level decreased from 1573 to
81 ng/mL (P = 0.002). Similarly, the median DCP level de-
creased from 4378 to 420 mAU/mL (P = 0.001). The OR
rate was 36.8%, and the disease control rate was 84.2%.
TACE was added at least once during repeated HAIC
in 19 patients (50%). There was no significant difference
in the baseline characteristics between patients with and
without additional TACE (Additional file 1: Table S1).
Among the 19 TACE cases, six (31.6%) underwent
TACE for residual tumor. In the remaining 13 cases
(68.4%), TACE was performed to control recurrent
lesions.
Pfs
Twenty-nine patients (76.4%) showed HCC progression
until the last follow-up visit (Table 2). First progression
was noted in out-of-field lesions in most cases (27/29,
93.1%). The most-frequent site of out-of-field progressed
lesions was the liver (15/27, 55.6%) (Table 3). The
median PFS was 7.4 (range: 1.8 − 32.1, 95% CI: 3.7-11.0)
months (Fig. 1). PFS was associated with the Child-Pugh
class (P = 0.020), baseline DCP level (P = 0.005), and
DCP level after CCRT (P < 0.001) in univariate analyses.
Multivariate Cox regression analysis using the back-
ward method revealed that DCP level after CCRT
(P = 0.001) was an independent factor related to PFS
(Table 4). The characteristics of patients with and with-
out progression was compared. There was no signifi-
cant difference (Additional file 1: Table S2.).
Os
The median overall survival duration was 11.6 (range:
2.8-65.7, 95% CI: 9.267-13.999) months (Fig. 2). The
characteristics of patients who survived and deceased
Table 1 Baseline characteristics
Characteristics n = 38
Age (years) 53 (34-77)
Male 33 (86.8)
Etiology
HBV 29 (76.3)
HCV 1 (4.8)
NBNC 8 (18.9)
Liver cirrhosis 30 (78.9)
Child-Pugh class (A/B)
Class A 32 (84.2)
Class B 6 (15.8)
ECOG performance status
Grade 0 5 (13.2)
Grade 1 33 (86.8)
Vascular invasion
Main portal trunk invasion 16 (42.1)
Left of right lobar portal vein invasion 15 (39.5)
Segmental portal vein invasion 5 (13.1)
Hepatic vein invasion 2 (5.3)
BCLC stage
Advanced (C) 38 (100)
AJCC stage
IIIB 20 (52.6)
IIIC 1 (2.6)
IVA 15 (39.5)
IVB 2 (5.3)
Tumor size (cm) 11.6 (3.5-21.1)
AFP (ng/mL) 1573.0 (2.0-54,000)
DCP (mAU/mL) 4378.0 (18.0-75,000)
Radiation dose (cGy) 4500 (3060-6250)
Round of HAIC 3.5 (0-18)
TACE 19 (50.0)
For local residual tumor 6 (31.6)
For newly recurring tumor 13 (68.4)
Variables are expressed as medians (range) or n (%)
HBV Hepatitis B virus, HCV Hepatitis C virus, NBNC Non-B and non-C, ECOG The
Eastern Cooperative Oncology Group, BCLC Barcelona Clinic Liver Cancer, AJCC
The American Joint Committee on Cancer, AFP α-fetoprotein, DCP Des-gamma
carboxyprothrombin, HAIC Hepatic arterial infusional chemotherapy, TACE
Transarterial chemoembolization
Table 2 Response after concurrent chemoradiation therapy
Response n = 38
Complete response -
Partial response 14 (36.8)
Stable disease 18 (47.4)
Progressive disease 6 (15.8)
Objective response (CR + PR) 14 (36.8)
Disease control (CR + PR + SD) 32 (84.2)
Variables are expressed as n (%). CR Complete response, PR Partial response,
SD Stable disease
Table 3 Characteristics of disease progression
Progression n = 38
No progression 9 (23.7)
Original lesion 2 (5.3)
New lesion 27 (71.1)
Liver 15 (55.6)
Lung 10 (37.0)
Bone 1 (3.7)
Neck node 1 (3.7)
Variables are expressed as n (%)
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were compared. Survived patients had no main portal
trunk invasion, achieved ORs after CCRT, and less DCP
levels after CCRT (Additional file 1: Table S3.). In
univariate analyses, patients with Child-Pugh class A
(P = 0.003), a PR after CCRT (P < 0.001), a lower DCP
level after CCRT (P = 0.001), additional TACE
(P = 0.001), and absence of main portal trunk invasion
(P = 0.040) showed a better OS (Table 5). Among these
factors, PR after CCRT (P < 0.001) and additional TACE
(P = 0.002) were independently and significantly posi-
tively related to OS. The patients were categorized into
four groups according to PR after CCRT and TACE;sur-
vival was significantly different among the four groups
(log-rank test, P < 0.001; Fig. 3). Patients with PR after
CCRT and additional TACE during repeated HAIC
showed a greater median survival duration than patients
with PR after CCRT and no additional TACE during re-
peated HAIC (44.2 vs. 14.7 months). Among patients
who did not achieve a PR after CCRT, those who under-
went additional TACE had a greater OS duration than
those who did not (11.2 vs. 6.2 months).
Discussion
Since the protocol of CCRT for advanced stage HCC
with portal invasion was introduced [11], favorable re-
sults have been reported; e.g., a median survival duration
of ≥11 months [19, 22–24]. In the current study, the me-
dian OS for CCRT was 11.6 months. By comparison, in
the Asian-Pacific sorafenib trial, which included Korean
patients, the median OS durations with and without
sorafenib were 6.5 and 4.2 months, respectively [7].
Although these results cannot be compared directly, the
overall outcomes of CCRT seem to be more favorable
than systemic treatment without localized treatment.
Although sorafenib is the recommended first-line
treatment for advanced stage HCC per the BCLC staging
system [8], in practice, its use is limited by its high cost,
reimbursement strategy, modest survival gain, and poor
tolerance. In cases in whichthe use of sorafenib is not
feasible, we apply radiation-based treatment using a
Numbers at risk    38                                 8                                 2      
Fig. 1 Progression-free survival (PFS) of the patients. The median
PFS duration was 7.4 months
Table 4 Predictors of progression free survival
Characteristic Univariate Multivariate
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age (per year) 0.997 0.962-1.033 0.861
Gender (male vs. female) 0.892 0.268-2.969 0.852
Liver cirrhosis (with vs. without) 0.939 0.401-2.202 0.886
Child-Pugh class (A vs. B) 0.304 0.111-0.829 0.020 0.461 0.155-1.366 0.162
Main portal trunk invasion
(with vs. without)
1.098 0.520-2.318 0.805
Node metastasis (with vs. without) 0.809 0.393-1.664 0.565
Baseline tumor size (per 1 cm) 1.045 0.958-1.140 0.317
Baseline AFP (per 100 ng/mL) 1.000 0.997-1.002 0.827
Baseline DCP (per 100 mAU/mL) 1.002 1.001-1.003 0.005
Radiation dose (per 100 cGy) 0.931 0.866-1.001 0.054
Objective response after CCRT
(with vs. without)
0.560 0.267-1.174 0.125
AFP after CCRT (per 100 ng/mL) 1.000 0.998-1.002 0.962
DCP after CCRT (per 100 mAU/mL) 1.004 1.002-1.006 <0.001 1.003 1.001-1.005 0.001
Additional TACE (with vs. without) 0.590 0.269-1.299 0.190
Round of HAIC 0.914 0.831-1.005 0.062
AFP α-fetoprotein, DCP Des-gamma carboxyprothrombin, CCRT Concurrent chemoradiation therapy, TACE Transarterial chemoembolization, HAIC Hepatic arterial
infusional chemotherapy
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median radiation dose of 45 Gy delivered in 25 fractions.
Owing to the efficacy of RT, first progression occurred
mainly due to development of new lesions outside of the
radiation field.
During repeated HAIC, TACE was added in half of the
cases in the current study. Although TACE is mainly
recommended for the treatment of HCC without vascu-
lar invasion, it can also be applied to these patients [25].
Most primary lesions after CCRT remained stable and
showed shrinkage of portal vein thrombosis. Thus,
TACE can be used to treat such primary lesions with or
without new lesions. Because TACE occludes tumor-
supplying arteries, it may exert a more potent antitumor
effect than HAIC.
PFS was related to the Child-Pugh class and baseline
and post-CCRT DCP levels in univariate analyses. How-
ever, the DCP level after CCRT was the only independ-
ent predictor of PFS. DCP level has been reported as an
effective tumor marker and is associated with large
tumor size, vascular invasion, intrahepatic metastases,
and a low grade of tumor cell differentiation [26]. A high
preoperative DCP level appears to be indicative of recur-
rence in small HCC and facilitates detection of HCC
recurrence after living-donor liver transplantation [27].
In this study, univariate analyses indicated that OS was
related to the Child-Pugh class, main portal trunk inva-
sion, achievement of an OR after CCRT, the DCP level
after CCRT, further rounds of HAIC and additional
TACE. However, achievement of an OR after CCRT,
additional TACE, and further rounds of HAIC were in-
dependent factors associated with a good OS. Although
OR after CCRT and further rounds of HAIC were fully
predictable factors of improved survival, additional
TACE between repeated HAIC after CCRT was, unex-
pectedly, an independent prognostic factor for improved
survival. This retrospective study aimed to identify the
factors affecting survival after CCRT to facilitate a future
pilot trial of a modified protocol to improve outcomes.
The original CCRT protocol included indefinite repeti-
tions of HAIC after CCRT. Our results suggest that a
Numbers at risk    38                 19                  9                    4                   1                   1 
Fig. 2 Overall survival of the patients. The median overall survival
duration was 11.6 months
Table 5 Predictors of overall survival
Characteristic Univariate Multivariate
Hazard ratio 95% CI P-value Hazard ratio 95% CI P-value
Age (per year) 0.990 0.952-1.029 0.601
Gender (male vs. female) 0.778 0.269-2.246 0.641
Liver cirrhosis (with vs. without) 1.011 0.430-2.377 0.980
Child-Pugh class (A vs.B) 0.245 0.090-0.668 0.003 0.436 0.155-1.226 0.116
Main portal trunk invasion
(with vs. without)
2.079 1.019-4.243 0.040 2.099 0.941-4.682 0.070
Node metastasis (with vs. without) 0.732 0.350-1.531 0.405
Baseline tumor size (per 1 cm) 0.912 0.830-1.002 0.056
Baseline AFP (per 100 ng/mL) 1.000 0.998-1.003 0.711
Baseline DCP (per 100 mAU/mL) 1.001 0.999-1.002 0.256
Radiation dose (per 100 cGy) 1.007 0.943-1.074 0.843
Objective response after CCRT
(with vs. without)
0.096 0.036-0.254 <0.001 0.028 0.005-0.148 <0.001
AFP after CCRT (per 100 ng/mL) 1.000 0.998-1.003 0.702
DCP after CCRT (per 100 mAU/mL) 1.003 1.001-1.004 0.001
Additional TACE (with vs. without) 0.296 0.137-0.641 0.001 0.134 0.047-0.383 <0.001
Round of HAIC 0.805 0708-0.915 0.001 0.742 0.626-0.880 0.001
AFP α-fetoprotein, DCP Des-gamma carboxyprothrombin, CCRT Concurrent chemoradiation therapy, TACE Transarterial chemoembolization, HAIC Hepatic arterial
infusional chemotherapy
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prospective randomized controlled trial to assess the ef-
fect of additional TACE after CCRT is required.
An early AFP response and OR are reportedly inde-
pendent factors associated with PFS and OS after repeated
HAIC followed by CCRT [28]. However, this response can
be measured only if a patient has an initially elevated AFP
level, and cannot be manipulated for the modification of
the protocol. However, we can consider additional TACE
after CCRT to improve OS in practice.
This study has several limitations. First, the sample
size was relatively small, and so the effect of additional
TACE needs to be confirmed in a future larger-scale
study, the sample size of which should be based on our
findings. Second, because of the retrospective nature of
this study, additional TACE procedures were performed
at various time points. To overcome this limitation, fu-
ture prospective studies should randomize the patients
receiving TACE and consider the timing of additional
TACE. Third, we could not perform a comparison of
therapeutic efficacy with the recommended treatment,
sorafenib. However, in a previous comparative study of
CCRT and other treatments involving propensity score
matching, CCRT showed a better OS than other treat-
ments [23]. Also, sorafenib treatment for Child-Pugh
class B patients was not eligible for national health in-
surance reimbursement.
Conclusions
Patients who achieved an OR after CCRT, underwent
additional TACE, and were subjected to further rounds of
HAIC following CCRT showed better survival after CCRT
for treatment of advanced-stage HCC with vascular inva-
sion. Further prospective studies are required to confirm
the positive effect of additional TACE after CCRT.
Additional file
Additional file 1: Table S1. Baseline characteristics according to
treatment after CCRT. Table S2. Baseline characteristics according to
progression after CCRT. Table S3. Baseline characteristics according to
survival. (DOCX 20 kb)
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